Machine learning and radiomics for predicting efficacy of programmed cell death protein 1 inhibitor for small cell lung cancer: A multicenter cohort study

Documenti analoghi

• Multi‐omics predictive model based on clinical, radiomic and genomic features for predicting the response of limited‐stage small cell lung cancer to definitive chemoradiotherapy
  di: Li Li, et al.
  Pubblicazione: (2024)
• In vitro PK/PD modeling of tyrosine kinase inhibitors in non‐small cell lung cancer cell lines
  di: Linda Wanika, et al.
  Pubblicazione: (2024)
• Longitudinal circulating tumour DNA dynamics predict failure patterns and efficacy of consolidation immunotherapy after chemoradiotherapy in locally advanced non‐small‐cell lung cancer
  di: Yu Wang, et al.
  Pubblicazione: (2024)
• Baseline multi‐omics signatures could predict therapeutic response to neoadjuvant anti‐PD‐1 immunochemotherapy in non‐small‐cell lung cancer
  di: Ailing Cao, et al.
  Pubblicazione: (2026)
• Tumour hepcidin levels as a biomarker for predicting response to immune checkpoint inhibition in advanced non‐small cell lung cancer
  di: Yuichiro Suzukawa, et al.
  Pubblicazione: (2026)